Clinical trial
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With…
NCT00121095 · Cytogen Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00121095 |
|---|---|
| Title | Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer |
| Official title | Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer |
| Lead sponsor | Cytogen Corporation, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Samarium Sm-153 lexidronam + Docetaxel |
| Enrollment | 69 |
| Start date | Jul 1, 2005 |
| Completion | Jun 1, 2008 |
| First posted | Jul 21, 2005 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: